Eris Lifesciences Limited (ERIS) - Total Liabilities
Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has total liabilities worth Rs34.70 Billion INR (≈ $375.25 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Eris Lifesciences Limited to see how much of total assets are deployed in long-term investments.
Eris Lifesciences Limited - Total Liabilities Trend (2012–2026)
This chart illustrates how Eris Lifesciences Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ERIS total asset value.
Eris Lifesciences Limited Competitors by Total Liabilities
The table below lists competitors of Eris Lifesciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neutron Holdings, Inc. Common Stock
NASDAQ:LIME
|
USA | $493.56 Million |
|
Hefei Metalforming Mach Tool
SHG:603011
|
China | CN¥2.50 Billion |
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
Germany | €5.01 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
Taiwan | NT$451.77 Billion |
|
Atea ASA
OL:ATEA
|
Norway | Nkr16.70 Billion |
|
Pfizer Limited
NSE:PFIZER
|
India | Rs-42.03 Billion |
|
L1 Group Limited
AU:L1G
|
Australia | AU$205.86 Million |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
USA | $4.22 Billion |
Liability Composition Analysis (2012–2026)
This chart breaks down Eris Lifesciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Eris Lifesciences Limited to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eris Lifesciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eris Lifesciences Limited (2012–2026)
The table below shows the annual total liabilities of Eris Lifesciences Limited from 2012 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs34.70 Billion ≈ $375.25 Million |
-7.75% |
| 2025-03-31 | Rs37.61 Billion ≈ $406.78 Million |
-1.71% |
| 2024-03-31 | Rs38.27 Billion ≈ $413.85 Million |
+164.53% |
| 2023-03-31 | Rs14.47 Billion ≈ $156.45 Million |
+297.50% |
| 2022-03-31 | Rs3.64 Billion ≈ $39.36 Million |
+40.87% |
| 2021-03-31 | Rs2.58 Billion ≈ $27.94 Million |
+0.93% |
| 2020-03-31 | Rs2.56 Billion ≈ $27.68 Million |
-33.49% |
| 2019-03-31 | Rs3.85 Billion ≈ $41.62 Million |
-32.97% |
| 2018-03-31 | Rs5.74 Billion ≈ $62.09 Million |
+468.02% |
| 2017-03-31 | Rs1.01 Billion ≈ $10.93 Million |
+6.92% |
| 2016-03-31 | Rs945.34 Million ≈ $10.22 Million |
+7.80% |
| 2015-03-31 | Rs876.95 Million ≈ $9.48 Million |
-2.28% |
| 2014-03-31 | Rs897.40 Million ≈ $9.71 Million |
+47.18% |
| 2013-03-31 | Rs609.72 Million ≈ $6.59 Million |
+24.04% |
| 2012-03-31 | Rs491.55 Million ≈ $5.32 Million |
-- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more